Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 10, 2017 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces First Dosing in RHB-105 Supportive PK Studies Ahead of Confirmatory Phase III Study for H. pylori Infection

The first group of subjects have been dosed in a single-dose three-way crossover pharmacokinetic (PK) study with RHB-105 versus the active comparators in the confirmatory Phase III study and in a...
January 09, 2017 09:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma’s RHB-105 Positive Phase III Study Results for H. pylori Infection Presented at the Innovations in Gastroenterology 2017 Symposium

TEL-AVIV, Israel, Jan. 09, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the...
January 09, 2017 06:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces Exercise of Stock Options by Directors and Senior Management

Members of RedHill’s Board of Directors, senior management and Advisory Board have exercised stock options to purchase an aggregate of 1,700,000 ordinary shares (equivalent to 170,000 American...
January 06, 2017 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces YELIVA® (ABC294640) Abstract Presentation at the 2017 Cholangiocarcinoma Foundation Annual Conference

The abstract, to be presented at the upcoming 2017 Cholangiocarcinoma Foundation Annual Conference, describes positive findings from non-clinical studies and the Phase I clinical study with YELIVA®...
January 05, 2017 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces New Research Collaboration with Aarhus University for Oncology Drug MESUPRON

The new research collaboration follows previous non-clinical studies conducted with Denmark’s Aarhus University and is designed to identify additional high affinity molecular targets of MESUPRON...
January 04, 2017 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma to Present the Positive Results of the First Phase III study with RHB-105 for H. pylori Infection at the Innovations in Gastroenterology 2017 Symposium

TEL-AVIV, Israel, Jan. 04, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the...
January 03, 2017 11:01 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces Exercise of Underwriters’ Option

TEL-AVIV, Israel, Jan. 03, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the...
January 03, 2017 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces Exclusive U.S. Co-Promotion Agreement with Concordia for GI Drug Donnatal®

RedHill and Concordia entered into an exclusive co-promotion agreement, granting RedHill certain U.S. promotion rights for Donnatal®Donnatal®1, Tablets and Elixir (syrup), is a prescription oral...
December 28, 2016 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma to Present at the Biotech Showcase 2017

TEL-AVIV, Israel, Dec. 28, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and...
December 27, 2016 10:12 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces Closing of Concurrent Public Offering and Registered Direct Offering of its American Depositary Shares and Warrants and Partial Exercise of the Option of Underwriters

TEL-AVIV, Israel, Dec. 27, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on the development...